Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Current Liabilities (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Total Current Liabilities for 5 consecutive years, with $125.0 million as the latest value for Q1 2026.

  • For Q1 2026, Total Current Liabilities rose 68.9% year-over-year to $125.0 million; the TTM value through Mar 2026 reached $125.0 million, up 68.9%, while the annual FY2025 figure was $132.0 million, 54.03% up from the prior year.
  • Total Current Liabilities hit $125.0 million in Q1 2026 for Phathom Pharmaceuticals, down from $132.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $132.0 million in Q4 2025 and bottomed at $11.4 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $55.2 million, with a median of $43.5 million recorded in 2024.
  • Year-over-year, Total Current Liabilities rose 2.23% in 2023 and then skyrocketed 200.9% in 2024.
  • Phathom Pharmaceuticals' Total Current Liabilities stood at $26.2 million in 2022, then soared by 47.81% to $38.8 million in 2023, then soared by 121.06% to $85.7 million in 2024, then surged by 54.03% to $132.0 million in 2025, then fell by 5.3% to $125.0 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $125.0 million, $132.0 million, and $93.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.